Format
Items per page
Sort by

Send to:

Choose Destination

Results: 12

1.

The clinical utility of serum anti-Müllerian hormone in the follow-up of ovarian adult-type granulosa cell tumors-A comparative study with inhibin B.

Färkkilä A, Koskela S, Bryk S, Alfthan H, Bützow R, Leminen A, Puistola U, Tapanainen JS, Heikinheimo M, Anttonen M, Unkila-Kallio L.

Int J Cancer. 2015 Mar 24. doi: 10.1002/ijc.29532. [Epub ahead of print]

PMID:
25808251
2.

Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor: a 56-year single-center experience.

Bryk S, Färkkilä A, Bützow R, Leminen A, Heikinheimo M, Anttonen M, Riska A, Unkila-Kallio L.

Int J Gynecol Cancer. 2015 Jan;25(1):33-41. doi: 10.1097/IGC.0000000000000304.

PMID:
25347095
3.

HER2 and GATA4 are new prognostic factors for early-stage ovarian granulosa cell tumor-a long-term follow-up study.

Färkkilä A, Andersson N, Bützow R, Leminen A, Heikinheimo M, Anttonen M, Unkila-Kallio L.

Cancer Med. 2014 Jun;3(3):526-36. doi: 10.1002/cam4.230. Epub 2014 Mar 29.

4.

Sensitivity of human granulosa cell tumor cells to epidermal growth factor receptor inhibition.

Andersson N, Anttonen M, Färkkilä A, Pihlajoki M, Bützow R, Unkila-Kallio L, Heikinheimo M.

J Mol Endocrinol. 2014 Mar 12;52(2):223-34. doi: 10.1530/JME-13-0286. Print 2014 Apr.

5.

FOXL2, GATA4, and SMAD3 co-operatively modulate gene expression, cell viability and apoptosis in ovarian granulosa cell tumor cells.

Anttonen M, Pihlajoki M, Andersson N, Georges A, L'hôte D, Vattulainen S, Färkkilä A, Unkila-Kallio L, Veitia RA, Heikinheimo M.

PLoS One. 2014 Jan 9;9(1):e85545. doi: 10.1371/journal.pone.0085545. eCollection 2014.

6.

Serum vascular endothelial growth factor A (VEGF) is elevated in patients with ovarian granulosa cell tumor (GCT), and VEGF inhibition by bevacizumab induces apoptosis in GCT in vitro.

Färkkilä A, Pihlajoki M, Tauriala H, Bützow R, Leminen A, Unkila-Kallio L, Heikinheimo M, Anttonen M.

J Clin Endocrinol Metab. 2011 Dec;96(12):E1973-81. doi: 10.1210/jc.2011-1812. Epub 2011 Oct 12.

PMID:
21994955
7.

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS.

Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Li D, Hartung HP, Krantz M, Ferenczi L, Verco T; MAESTRO-01 Investigators.

Neurology. 2011 Oct 18;77(16):1551-60. doi: 10.1212/WNL.0b013e318233b240. Epub 2011 Oct 5.

PMID:
21975206
8.

Anti-Müllerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis.

Anttonen M, Färkkilä A, Tauriala H, Kauppinen M, Maclaughlin DT, Unkila-Kallio L, Bützow R, Heikinheimo M.

Lab Invest. 2011 Nov;91(11):1605-14. doi: 10.1038/labinvest.2011.116. Epub 2011 Aug 1.

9.

Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors.

Färkkilä A, Anttonen M, Pociuviene J, Leminen A, Butzow R, Heikinheimo M, Unkila-Kallio L.

Eur J Endocrinol. 2011 Jan;164(1):115-22. doi: 10.1530/EJE-10-0849. Epub 2010 Nov 1.

10.

Vascular endothelial growth factor-C accelerates diabetic wound healing.

Saaristo A, Tammela T, Farkkilā A, Kärkkäinen M, Suominen E, Yla-Herttuala S, Alitalo K.

Am J Pathol. 2006 Sep;169(3):1080-7.

11.

Disturbance of the water and electrolyte balance during high-dose interferon treatment.

Färkkilä AM, Iivanainen MV, Färkkilä MA.

J Interferon Res. 1990 Apr;10(2):221-7.

PMID:
2341751
12.

Low platelet arachidonic acid in young patients with brain infarction.

Färkkilä MA, Rasi V, Tilvis RS, Ikkala E, Viinikka L, Ylikorkala O, Färkkilä AM, Miettinen TA.

Thromb Res. 1987 Dec 15;48(6):721-7.

PMID:
2829382
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk